Steinar Johan Engelsen
Chief Executive Officer bei Engelsen Invest AS
Profil
Steinar Johan Engelsen is currently the Chairman & Managing Director at Engelsen Invest.
AS since 2001 and a Partner at Teknoinvest AS since 1996.
He previously served as the Chief Executive Officer at Centaur Pharmaceuticals, Inc. in 2000 and as an Independent Director at Insmed, Inc. from 1999 to 2022.
He also served as an Independent Director at Soleno Therapeutics, Inc. from 2004 to 2017, and as a Director at INSMED Pharmaceuticals, Inc., Affitech AS, Holberg EEG AS, and Angiogenix, Inc. He has a background in research and development, having served as Senior Vice President-Research & Development at Takeda AS, Hafslund Nycomed AS, and Nycomed Pharma Holding A.
He holds a graduate and doctorate degree from the University of Oslo.
Aktive Positionen von Steinar Johan Engelsen
| Unternehmen | Position | Beginn |
|---|---|---|
Teknoinvest AS
 Teknoinvest AS Investment ManagersFinance Teknoinvest AS (Teknoinvest) is a venture capital firm headquartered in Oslo, Norway, with offices in New York, and Stockholm, Sweden. The firm was founded in 1984 by Bjørn Bjorå. | Private Equity Investor | 01.01.1996 |
Engelsen Invest AS
 Engelsen Invest AS Financial ConglomeratesFinance Engelsen Invest AS operates as a venture capital firm. It engages in portfolio investment services. The firm provides investment services such as investment trusts. The company was founded on June 15, 2001 and is headquartered in Stabekk, Norway. | Chief Executive Officer | 17.06.2011 |
Ehemalige bekannte Positionen von Steinar Johan Engelsen
| Unternehmen | Position | Ende |
|---|---|---|
| INSMED INCORPORATED | Director/Board Member | 11.05.2022 |
| SOLENO THERAPEUTICS, INC. | Director/Board Member | 31.12.2017 |
Affitech AS /Old/
 Affitech AS /Old/ Miscellaneous Commercial ServicesCommercial Services Affitech AS discovers and develops human therapeutic antibodies. It focuses on molecule and cell based antibody discovery. The company was founded by Martin Welschof, Ole Jorgen Marvik, and Michael Braunagel in 1997 and is headquartered in Oslo, Norway. | Director/Board Member | 16.06.2009 |
Angiogenix, Inc.
 Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA | Director/Board Member | 06.03.2008 |
| Centaur Pharmaceuticals, Inc. | Chief Executive Officer | 01.11.2000 |
Ausbildung von Steinar Johan Engelsen
| University of Oslo | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| INSMED INCORPORATED | Health Technology |
| SOLENO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
| Centaur Pharmaceuticals, Inc. | Health Technology |
Angiogenix, Inc.
Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA | Health Technology |
Teknoinvest AS
Teknoinvest AS Investment ManagersFinance Teknoinvest AS (Teknoinvest) is a venture capital firm headquartered in Oslo, Norway, with offices in New York, and Stockholm, Sweden. The firm was founded in 1984 by Bjørn Bjorå. | Finance |
Takeda AS
 Takeda AS Pharmaceuticals: MajorHealth Technology Takeda AS operates as a pharmaceutical company. It manufactures and distributes generic medicines. The firm offers therapeutics in the areas such as cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management. The company founded by Morten Nyegaard in 1874 and is headquartered in Asker, Norway. | Health Technology |
INSMED Pharmaceuticals, Inc.
 INSMED Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology INSMED Pharmaceuticals, Inc. develops products for the diagnosis and treatment of conditions associated with insulin resistance. The company is headquartered in Richmond, VA. | Health Technology |
| Hafslund Nycomed AS | Health Technology |
Nycomed Pharma Holding A/S
 Nycomed Pharma Holding A/S Pharmaceuticals: GenericHealth Technology Nycomed Pharma Holding A/S operates as a holding company with an interest in manufacturing generic drugs. It is active in therapeutic areas, such as cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management. The company develops, manufactures, and markets products through Nycomed Pharma A/S. Nycomed Pharma Holding is headquartered in Roskilde, Denmark. | Health Technology |
Affitech AS /Old/
Affitech AS /Old/ Miscellaneous Commercial ServicesCommercial Services Affitech AS discovers and develops human therapeutic antibodies. It focuses on molecule and cell based antibody discovery. The company was founded by Martin Welschof, Ole Jorgen Marvik, and Michael Braunagel in 1997 and is headquartered in Oslo, Norway. | Commercial Services |
Engelsen Invest AS
Engelsen Invest AS Financial ConglomeratesFinance Engelsen Invest AS operates as a venture capital firm. It engages in portfolio investment services. The firm provides investment services such as investment trusts. The company was founded on June 15, 2001 and is headquartered in Stabekk, Norway. | Finance |
Holberg EEG AS
 Holberg EEG AS Packaged SoftwareTechnology Services Holberg EEG AS develops systematic computer based classification and reporting software. Its products for standardised structural interpretation, reporting and sharing of advanced diagnostic data and is currently focused in the field of electroencephalography. The company was founded by Harald Aurlien and Jan Brgger in 2009 and is headquartered in Bergen, Norway. | Technology Services |
